← The Wire
VRTXNasdaq
VERTEX PHARMACEUTICALS INC / MA
Pharmaceutical Preparations · MA · CIK 875320
Discovers and develops small-molecule drugs and gene-editing therapies for serious diseases
red 8-K · 90d🔥 High media attention
$112.92B
Market cap
$499.65
Last close
+1.7%
1D
+7.0%
5D
2.1M
Volume
Price · last 39 sessions+16.2%
May 4L $424.36 · H $499.65Jun 29
92
Total filings
May 13, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteMay 13, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 4, 2026DEFA14ADEFA14AApr 29, 20268-KExecutive ChangeApr 29, 2026DEFA14ADEFA14AApr 2, 2026DEF 14ADEF 14AApr 2, 20268-KCompany UpdateMar 31, 202610-K10-KFeb 13, 20268-KResults of OperationsFeb 12, 202610-Q10-QNov 4, 20258-KResults of OperationsNov 3, 202510-Q10-QAug 5, 20258-KExecutive Change · Results of OperationsAug 4, 20258-KCompany UpdateMay 19, 20258-KShareholder VoteMay 14, 202510-Q10-QMay 6, 20258-KResults of OperationsMay 5, 2025DEFA14ADEFA14AApr 3, 2025DEF 14ADEF 14AApr 3, 20258-KCompany UpdateMar 28, 202510-K10-KFeb 13, 20258-KExecutive Change · Results of OperationsFeb 10, 20258-KReg FD DisclosureDec 20, 202410-Q10-QNov 5, 20248-KResults of OperationsNov 4, 20248-KMaterial AgreementAug 16, 202410-Q10-QAug 2, 20248-KResults of OperationsAug 1, 20248-KCompany UpdateJun 27, 20248-KCompany UpdateMay 20, 20248-KShareholder VoteMay 15, 202410-Q10-QMay 7, 20248-KResults of OperationsMay 6, 20248-KMaterial Agreement · Company UpdateApr 11, 2024DEFA14AVERTEX PHARMACEUTICALS INC - DEFA14AApr 4, 2024DEF 14AVERTEX PHARMACEUTICALS INC - DEF 14AApr 4, 202410-K10-KFeb 15, 20248-KResults of OperationsFeb 5, 2024SC 13GSC 13GJan 25, 20248-KCompany UpdateDec 8, 20238-KExecutive ChangeDec 5, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 6, 20238-KExecutive ChangeOct 5, 202310-Q10-QAug 2, 20238-KResults of OperationsAug 1, 20238-KShareholder VoteMay 18, 202310-Q10-QMay 2, 20238-KResults of OperationsMay 1, 2023DEFA14AVERTEX PHARMACEUTICALS INC - DEFA14AApr 6, 2023DEF 14AVERTEX PHARMACEUTICALS INC - DEF 14AApr 6, 2023SC 13GSEC SCHEDULE 13GFeb 13, 202310-K10-KFeb 10, 2023SC 13GSC 13GFeb 9, 20238-KResults of OperationsFeb 7, 2023SC 13GSC 13GJan 24, 202310-Q10-QOct 28, 20228-KResults of OperationsOct 27, 202210-Q10-QAug 5, 20228-KResults of OperationsAug 4, 20228-KCompany UpdateJul 11, 20228-KMaterial Agreement · Agreement TerminatedJul 5, 20228-KCompany UpdateMay 23, 20228-KShareholder VoteMay 18, 202210-Q10-QMay 6, 20228-KResults of OperationsMay 5, 2022DEFA14AVERTEX PHARMACEUTICALS INC - DEFA14AApr 7, 2022DEF 14AVERTEX PHARMACEUTICALS INC - DEF 14AApr 7, 202210-K10-KFeb 9, 20228-KResults of OperationsJan 26, 202210-Q10-QNov 3, 20218-KResults of OperationsNov 2, 202110-Q10-QJul 30, 20218-KResults of OperationsJul 29, 20218-KCompany UpdateJun 24, 20218-KShareholder VoteMay 19, 202110-Q10-QApr 30, 20218-KResults of OperationsApr 29, 20218-KMaterial AgreementApr 20, 2021
Insider Activity
In the 90 days to Mar 27, 2026: 12 sold $76.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 27, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $450.95 | $1.1M |
| Mar 13, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $481.79 | $1.1M |
| Mar 11, 2026 | Mckechnie DuncanEVP, Chief Commercial Officer | Sell | 2,633 | $498.42 | $1.3M |
| Mar 4, 2026 | Mckechnie DuncanEVP, Chief Commercial Officer | Sell | 2,437 | $475.30 | $1.2M |
| Mar 2, 2026 | Liu JoyEVP and Chief Legal Officer | Sell | 892 | $495.96 | $442K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 15,580 | $495.38 | $7.7M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 5,995 | $496.16 | $3.0M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 3,498 | $494.33 | $1.7M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 3,278 | $488.27 | $1.6M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,725 | $490.54 | $1.3M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,520 | $493.29 | $1.2M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 2,510 | $487.13 | $1.2M |
| Feb 27, 2026 | Bozic CarmenEVP and CMO | Sell | 2,329 | $480.31 | $1.1M |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 1,725 | $496.95 | $857K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 949 | $491.30 | $466K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 460 | $489.32 | $225K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 400 | $479.75 | $192K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 240 | $482.84 | $116K |
| Feb 27, 2026 | Kewalramani ReshmaCEO & President | Sell | 120 | $481.50 | $58K |
| Feb 26, 2026 | Ambrose KristenSVP & Chief Accounting Officer | Sell | 357 | $483.36 | $173K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 12 reputable articles · skews ▲ positive.
MarketWatchVertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains3d agoMarketWatchVertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains4d agoMarketWatchVertex Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains7d agoMarketWatchVertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day11d agoMarketWatchVertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day12d agoMarketWatchVertex Pharmaceuticals Inc. stock rises Monday, still underperforms market14d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance